ÂÜÀòÂÒÂ×

Andy Scharenberg is an accomplished leader in the biopharmaceutical industry, currently serving as Chief Executive Officer of Umoja Biopharma and Executive Partner at MPM BioImpact since 2019. Scharenberg also holds positions as Chair of the Scientific Advisory Boards for both Alpine Immune Sciences and Generation Bio. With extensive academic experience, Scharenberg was a Professor of Pediatrics and Immunology at the University of Washington and a Principal Investigator at Seattle Children's Hospital from 2000 to 2020. Previous roles include Chief Scientific Officer at Casebia Therapeutics and Cellectis Therapeutics, where Scharenberg played a crucial role in developing gene editing technologies. Scharenberg obtained a Doctor of Medicine degree from the University of North Carolina School of Medicine.